Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms BIRCH
  • Sponsors Chugai Pharmaceutical; Genentech; Roche
  • Most Recent Events

    • 15 Apr 2019 Results of pooled analysis of four clinical trials (NCT02031458, NCT01846416, NCT02008227,NCT01903993) evaluating whether lung immune prognostic index is predictive of survival and response for patients treated with atezolizumab for advanced non-small cell lung cancer, published in the Journal of Thoracic Oncology.
    • 22 Mar 2019 This trial has been completed in Slovenia, according to European Clinical Trials Database.
    • 25 Jan 2019 This trial has been completed in France, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top